Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 1, 1997Circulation

First Chronic Platelet Glycoprotein IIb/IIIa Integrin Blockade

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does oral xemilofiban inhibit platelet aggregation and is it safe in patients with unstable angina undergoing percutaneous coronary interventions?

Population

30 patients with unstable angina undergoing percutaneous coronary interventions

Comparison

Xemilofiban 35 mg orally before and 20 to 25 mg… vs Placebo

Design

RCT, randomized

Follow-up

30 days

Authors

CSConrad SimpfendorferCleveland ClinicKKKandice Kottke‐MarchantCleveland ClinicMLMarsha LowrieCleveland Clinic

Discussion

Loading...

Member takes

Implication

Xemilofiban delivers rapid sustained platelet inhibition; extends oral GPIIb/IIIa evidence but bleeding risk cautions against routine PCI use.

Structured PICO

Does oral xemilofiban inhibit platelet aggregation and is it safe in patients with unstable angina undergoing percutaneous coronary interventions?

P
Population
30 patients with unstable angina undergoing percutaneous coronary interventions
I
Intervention
Xemilofiban 35 mg orally before and 20 to 25 mg three times daily for 30 days after angioplasty
C
Comparator
Placebo
O
Outcome
Bleeding events, platelet aggregation, and pharmacokinetic and hematologic parameters assessed during hospitalization and at 2 and 4 weeks after drug initiationsurrogate

Oral xemilofiban provides rapid and sustained platelet inhibition but is associated with significant major and mucocutaneous bleeding at the tested doses.

Cite This Study

Simpfendorfer et al. (1997) studied this question.

synapsesocial.com/papers/6a726c7c35aa2c282ce33ea5https://doi.org/10.1161/01.cir.96.1.76
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The role of platelets in arterial thrombosis and the rationale for blockade of platelet GPIIb/IIIa receptors as antithrombotic therapy1995 · 71 citations
  2. 2The Effects of Two Synthetic Glycoprotein II b/III a Antagonists, Ro 43-8857 and L-700,462, on Platelet Aggregation and Bleeding in Guinea-Pigs and Dogs: Evidence that Ro 43-8857 Is Orally Active1993 · 36 citations
  3. 3New Antiplatelet Agents: Platelet GPIIb/llla Antagonists1995 · 103 citations
  4. 4Aspirin and Dipyridamole in the Prevention of Re-Stenosis after Percutaneous Transluminal Coronary Angioplasty1988 · 694 citations
  5. 5SC-54684A: An Orally Active Inhibitor of Platelet Aggregation1995 · 65 citations